Hosted by Petauri Evidence · 🇺🇸 US · EN-US · 74 episodes
Established thought leaders with verified media credentials.
We explore news and insights from global healthcare markets, advising how pharma and medtech need to respond and adapt their market access strategy in light of the latest insights from our experts. The podcast features insights from our associates across global healthcare, along with thought leadership from the market access and HEOR experts at Petauri Evidence.
Petauri Evidence hosts Pharma Market Access Insights - from Petauri Evidence, a science show with 74 episodes published.
Send us Fan Mail How will Most Favored Nation (MFN) pricing reshape global pharmaceutical strategy? What do emerging Centers for Medicare & Medicaid Service (CMS) models such as GENEROUS, GLOBE, and GUARD mean for launch
Send us Fan Mail How do LATAM healthcare markets differ and what do these differences mean for Pharma and Medtech launch planning? What should global market access teams know to support affiliates in Argentina, Brazil, C
Send us Fan Mail What does the evolving NHS landscape look like through the eyes of a Chief Pharmacist, and how are integrated care system (ICS) pharmacy teams responding? In this Petauri Evidence NHS Whispers session, w
Send us Fan Mail What makes Switzerland a compelling first-launch market for Pharma? How does its healthcare system compare to other European countries? What do manufacturers need to know about reimbursement, pricing, an
Send us Fan Mail In this NHS Whispers live Q&A webinar, Katie Mulholland (Senior Consultant, UK Market Access, Petauri Evidence) speaks to: - Sarah Everest Ford (Programme Director, Health and Care Partnership) - Patrick
Send us Fan Mail Uncover the forces driving change in global pricing and access In this expert-led discussion we explore the latest trends, challenges, and strategic considerations shaping global pricing and market acces
Send us Fan Mail Discover a smarter way to manage and share market access resources with local affiliates Are your global market access resources scattered, leading to inconsistencies and confusion among your affiliates?
Send us Fan Mail What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepa
Send us Fan Mail Discover how health economics can support successful Medical Device launch, proposition development, and market access This episode offers an insightful journey into the world of medical device market ac
Send us Fan Mail What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be ge
Send us Fan Mail How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?
Send us Fan Mail How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months? In August, Karen
Send us Fan Mail Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NH
Send us Fan Mail What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the bigges
Send us Fan Mail Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting de
Send us Fan Mail What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In thi
Send us Fan Mail Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you
Send us Fan Mail Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders? We sit down with guest sp
Send us Fan Mail What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on th
Send us Fan Mail What is health economic evaluation and which modelling approaches can be used to support market access activities? In this episode, our expert health economists explain the key strengths and limitations
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Pharma Market Access Insights - from Petauri Evidence has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Pharma Market Access Insights - from Petauri Evidence is hosted by Petauri Evidence. The show is categorised under science (life) and has published 74 episodes.
Pharma Market Access Insights - from Petauri Evidence has published 74 episodes.
Pharma Market Access Insights - from Petauri Evidence regularly covers science, life, business. It sits in the science category, with a life focus.
Pharma Market Access Insights - from Petauri Evidence is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Pharma Market Access Insights - from Petauri Evidence hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Pharma Market Access Insights - from Petauri Evidence average 53 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates Pharma Market Access Insights - from Petauri Evidence's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched today.